Clinical efficacy analysis of clarithromycin combined with triple therapy in the treatment of Helicobacter pylori infection related gastritis
克拉霉素联合三联疗法治疗幽门螺旋杆菌感染相关胃炎的临床效果分析

摘要

目的 探究克拉霉素与三联疗法联用对幽门螺旋杆菌感染相关胃炎的临床治疗效果。方法 将我院于2024年2月~2025年2月收治的幽门螺旋杆菌感染相关胃炎患者80例设为研究样本，依照信封随机分组法分成参考组（三联疗法）与实验组（克拉霉素联合三联疗法）两组，每组40例。对比两组的效果差异。结果 在症状积分方面，治疗前，两组无显著差异（P＞0.05），治疗后，实验组的反酸、嗳气及上腹疼痛积分均明显更低（P<0.05）；在治疗有效率上，实验组明显更高（P<0.05）。结论 克拉霉素与三联疗法联用方案在幽门螺旋杆菌感染相关性胃炎的治疗中疗效优异，能有效改善患者症状，提高治疗有效率。

Abstract

Objective To investigate the clinical therapeutic effect of clarithromycin combined with triple therapy on Helicobacter pylori infection related gastritis.
Methods 80 patients with Helicobacter pylori infection related gastritis admitted to our hospital from February 2024 to February 2025 were selected as the study sample. They were randomly divided into a reference group (triple therapy) and an experimental group (clarithromycin combined triple therapy) using envelope randomization, with 40 patients in each group. Compare the differences in effectiveness between the two groups.
Results In terms of symptom scores, there was no significant difference between the two groups before treatment (P>0.05). After treatment, the experimental group had significantly lower scores for acid reflux, belching, and upper abdominal pain (P<0.05); In terms of treatment effectiveness, the experimental group was significantly higher (P<0.05).
Conclusion   The combination therapy of clarithromycin and triple therapy has excellent therapeutic effects in the treatment of Helicobacter pylori infection related gastritis, effectively improving patient symptoms and enhancing treatment efficacy.